The results of a large-sample phase III clinical trial with the participation of 67 research centers across the world show that: 32% of the e-antigen positive chronic hepatitis B patients become e-antigen negative at the time of half a year after stopping the administration of Pegasys, a long-acting interferon, for 48 weeks.